10x Genomics, Inc.
Company Stats
- Market Cap
- $11.8B
- as of Sep 30, 2026
- Shares Outstanding
- 130.3M
- Free Float
- 84.6%
Income Statement
- Revenue
- $642.8M
- Operating Income
- -$61.0M
- Net Income
- -$43.5M
- EBITDA
- -$24.8M
- Non-cash Impairment
- $2.1M
- Revenue Growth, 3Y
- 7.6%
- FCF Margin, 3Y Avg
- 3.0%
- FCF Margin, Worst Year
- -10.3%
Cash Flow
- Free Cash Flow
- $130.1M
- FCF Yield
- 1.1%
- Owner FCF Yield
- 0.2%
Returns & Capital
- SBC, 3Y Avg
- $138.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $642.8M | $130.1M | 20.2% |
| FY2024 | $610.8M | -$5.7M | -0.9% |
| FY2023 | $618.7M | -$63.8M | -10.3% |
| FY2022 | $516.4M | -$165.3M | -32.0% |
| FY2021 | $490.5M | -$122.7M | -25.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 16, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges